# Opus Genetics Inc. (IRD)

Source: https://www.quantisnow.com/company/IRD
Generated: 2026-11-08T04:35:23.053Z

- Ticker: IRD
- Exchange: NASDAQ
- Sector: Health Care
- Industry: Biotechnology: Pharmaceutical Preparations
- SEC CIK: 0001228627

## Latest IRD news and filings

- 2026-11-05 21:04 UTC [SEC Form 4] [Chief Executive Officer Magrath George sold $110,184 worth of shares (28,258 units at $3.90), decreasing direct ownership by 1% to 2,010,636 units (SEC Form 4) to satisfy withholding tax](https://www.quantisnow.com/insight/chief-executive-officer-magrath-george-sold-110184-worth-of-shares-6776011)
- 2026-11-05 12:00 UTC [Opus Genetics Completes Dosing in Cohort 2 of Phase 1/2 Clinical Trial of OPGx-BEST1 Gene Therapy for Inherited Retinal Diseases](https://www.quantisnow.com/insight/opus-genetics-completes-dosing-in-cohort-2-of-phase-12-6774405)
- 2026-11-03 12:00 UTC [Conference Announcement] [Opus Genetics to Present at the Guggenheim Annual Healthcare Innovation Conference](https://www.quantisnow.com/insight/opus-genetics-to-present-at-the-guggenheim-annual-healthcare-innovation-6768384)
- 2026-11-02 21:39 UTC [Opus Genetics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)](https://www.quantisnow.com/insight/opus-genetics-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-6767572)
- 2026-10-29 11:00 UTC [Leadership Update] [Opus Genetics Appoints Dr. Andrew Murphy as Chief Scientific Officer and Jamie Lynne Hart as Executive Director, Executive Operations](https://www.quantisnow.com/insight/opus-genetics-appoints-dr-andrew-murphy-as-chief-scientific-officer-6762340)
- 2026-10-27 20:47 UTC [SEC Form 4] [Chief Operating Officer Schachle Joseph K sold $16,994 worth of shares (4,767 units at $3.57) (SEC Form 4)](https://www.quantisnow.com/insight/chief-operating-officer-schachle-joseph-k-sold-16994-worth-of-6759592)
- 2026-10-27 20:41 UTC [SEC Form 4] [President Yerxa Benjamin R sold $117,365 worth of shares (33,189 units at $3.54) (SEC Form 4)](https://www.quantisnow.com/insight/president-yerxa-benjamin-r-sold-117365-worth-of-shares-33189-6759572)
- 2026-10-27 20:29 UTC [SEC Form 4] [Chief Financial Officer Gagnon Robert E. sold $49,650 worth of shares (14,000 units at $3.55) as part of a pre-agreed trading plan (SEC Form 4)](https://www.quantisnow.com/insight/chief-financial-officer-gagnon-robert-e-sold-49650-worth-of-6759493)
- 2026-10-27 20:20 UTC [SEC Form 4] [Chief Executive Officer Magrath George sold $34,384 worth of shares (9,591 units at $3.59) (SEC Form 4)](https://www.quantisnow.com/insight/chief-executive-officer-magrath-george-sold-34384-worth-of-shares-6759408)
- 2026-10-23 20:57 UTC [SEC Form 144] [SEC Form 144 filed by Opus Genetics Inc.](https://www.quantisnow.com/insight/sec-form-144-filed-by-opus-genetics-inc-6756522)
- 2026-10-21 20:05 UTC [SEC Form 8-K] [SEC Form 8-K filed by Opus Genetics Inc.](https://www.quantisnow.com/insight/sec-form-8-k-filed-by-opus-genetics-inc-6753489)
- 2026-10-16 16:00 UTC [Opus Genetics Announces FDA Approval of Phentolamine Ophthalmic Solution 0.75% for the Treatment of Presbyopia](https://www.quantisnow.com/insight/opus-genetics-announces-fda-approval-of-phentolamine-ophthalmic-solution-075-6748977)
- 2026-10-15 21:23 UTC [SEC Form 8-K] [SEC Form 8-K filed by Opus Genetics Inc.](https://www.quantisnow.com/insight/sec-form-8-k-filed-by-opus-genetics-inc-6748373)
- 2026-10-15 20:00 UTC [Opus Genetics Presents Positive Clinical Data from OPGx-BEST1 and OPGx-LCA5 Gene Therapy Programs at Retina in Rio 2026](https://www.quantisnow.com/insight/opus-genetics-presents-positive-clinical-data-from-opgx-best1-and-opgx-lca5-6747908)
- 2026-10-13 11:00 UTC [Conference Announcement] [Opus Genetics to Present at the Chardan Annual Healthcare Conference](https://www.quantisnow.com/insight/opus-genetics-to-present-at-the-chardan-annual-healthcare-conference-6744034)
- 2026-10-02 23:47 UTC [SEC Form 4] [Director Foundation Fighting Blindness Retinal Degeneration Fund sold $2,755,981 worth of shares (556,000 units at $4.96) (SEC Form 4)](https://www.quantisnow.com/insight/director-foundation-fighting-blindness-retinal-degeneration-fund-sold-2755981-worth-6735627)
- 2026-09-11 20:09 UTC [SEC Form 4] [Chief Executive Officer Magrath George exercised 392,157 shares at a strike of $1.15 and covered exercise/tax liability with 75,541 shares, increasing direct ownership by 18% to 2,048,485 units (SEC Form 4)](https://www.quantisnow.com/insight/chief-executive-officer-magrath-george-exercised-392157-shares-at-a-6712989)
- 2026-09-11 11:48 UTC [SEC Form 8-K] [Opus Genetics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits](https://www.quantisnow.com/insight/opus-genetics-inc-filed-sec-form-8-k-regulation-fd-disclosure-6712441)
- 2026-09-10 18:12 UTC [Public Offering] [Big Pharma Setbacks Create a New Wave of Rebound Plays](https://www.quantisnow.com/insight/big-pharma-setbacks-create-a-new-wave-of-rebound-plays-6711396)
- 2026-09-09 15:55 UTC [Public Offering] [Four Biotech Stories Heating Up Right Now](https://www.quantisnow.com/insight/four-biotech-stories-heating-up-right-now-6709786)
- 2026-09-09 11:30 UTC [SEC Form 8-K] [Opus Genetics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits](https://www.quantisnow.com/insight/opus-genetics-inc-filed-sec-form-8-k-regulation-fd-disclosure-6709242)
- 2026-09-09 11:00 UTC [Earnings Date] [Opus Genetics Announces Positive Low Dose Cohort 1 Data from Phase 1/2 Clinical Trial of OPGx-BEST1 and Successful FDA Type C Meeting with Potential Phase 3 Dosing in 2027](https://www.quantisnow.com/insight/opus-genetics-announces-positive-low-dose-cohort-1-data-from-6709135)
- 2026-09-08 20:05 UTC [SEC Form 4] [Chief Financial Officer Gagnon Robert E. sold $127,212 worth of shares (28,000 units at $4.54) as part of a pre-agreed trading plan, decreasing direct ownership by 5% to 556,375 units (SEC Form 4) to cover withholding tax](https://www.quantisnow.com/insight/chief-financial-officer-gagnon-robert-e-sold-127212-worth-of-6708244)
- 2026-09-08 20:05 UTC [SEC Form 4] [Director Gallagher Cam exercised 784,314 shares at a strike of $1.15, increasing direct ownership by 39% to 2,800,111 units (SEC Form 4)](https://www.quantisnow.com/insight/director-gallagher-cam-exercised-784314-shares-at-a-strike-of-6708243)
- 2026-09-02 11:00 UTC [Earnings Date] [Opus Genetics to Present OPGx-BEST1 Cohort 1 Clinical Data in Investor Webcast and at Upcoming Leading Ophthalmology Conferences](https://www.quantisnow.com/insight/opus-genetics-to-present-opgx-best1-cohort-1-clinical-data-in-6702244)
- 2026-08-19 20:05 UTC [Leadership Update] [Longeveron Appoints Nirav Jhaveri as Chief Financial Officer](https://www.quantisnow.com/insight/longeveron-appoints-nirav-jhaveri-as-chief-financial-officer-6688276)
- 2026-08-19 20:01 UTC [Opus Genetics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)](https://www.quantisnow.com/insight/opus-genetics-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-6688223)
- 2026-08-17 04:15 UTC [SEC Form EFFECT] [SEC Form EFFECT filed by Opus Genetics Inc.](https://www.quantisnow.com/insight/sec-form-effect-filed-by-opus-genetics-inc-6684074)
- 2026-08-14 21:19 UTC [Amendment: SEC Form SCHEDULE 13G/A filed by Opus Genetics Inc.](https://www.quantisnow.com/insight/amendment-sec-form-schedule-13ga-filed-by-opus-genetics-inc-6683723)
- 2026-08-14 10:03 UTC [Amendment: SEC Form SCHEDULE 13G/A filed by Opus Genetics Inc.](https://www.quantisnow.com/insight/amendment-sec-form-schedule-13ga-filed-by-opus-genetics-inc-6681673)
- 2026-08-07 00:24 UTC [SEC Form S-3] [SEC Form S-3 filed by Opus Genetics Inc.](https://www.quantisnow.com/insight/sec-form-s-3-filed-by-opus-genetics-inc-6670360)
- 2026-08-06 20:32 UTC [SEC Form 10-Q] [SEC Form 10-Q filed by Opus Genetics Inc.](https://www.quantisnow.com/insight/sec-form-10-q-filed-by-opus-genetics-inc-6669601)
- 2026-08-06 11:04 UTC [SEC Form 8-K] [Opus Genetics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits](https://www.quantisnow.com/insight/opus-genetics-inc-filed-sec-form-8-k-results-of-operations-6667170)
- 2026-08-06 11:00 UTC [Earnings] [Opus Genetics Announces Financial Results for Second Quarter 2026 and Provides Corporate Update](https://www.quantisnow.com/insight/opus-genetics-announces-financial-results-for-second-quarter-2026-and-6667068)
- 2026-08-03 11:00 UTC [Opus Genetics Completes Patient Enrollment in Registrational Phase 3 Trial of OPGx-LCA5 for LCA5-Associated Inherited Retinal Disease](https://www.quantisnow.com/insight/opus-genetics-completes-patient-enrollment-in-registrational-phase-3-trial-6658606)
- 2026-07-29 12:06 UTC [Analyst Coverage Initiated] [TD Cowen initiated coverage on Opus Genetics](https://www.quantisnow.com/insight/td-cowen-initiated-coverage-on-opus-genetics-6652839)
- 2026-07-27 20:08 UTC [SEC Form 4] [President Yerxa Benjamin R sold $22,064 worth of shares (7,429 units at $2.97), decreasing direct ownership by 1% to 704,106 units (SEC Form 4) to satisfy withholding tax](https://www.quantisnow.com/insight/president-yerxa-benjamin-r-sold-22064-worth-of-shares-7429-6649665)
- 2026-07-27 20:07 UTC [SEC Form 4] [Chief Operating Officer Schachle Joseph K sold $13,653 worth of shares (4,644 units at $2.94), decreasing direct ownership by 2% to 291,440 units (SEC Form 4) (withholding tax)](https://www.quantisnow.com/insight/chief-operating-officer-schachle-joseph-k-sold-13653-worth-of-6649657)
- 2026-07-27 20:07 UTC [SEC Form 4] [Chief Executive Officer Magrath George sold $27,926 worth of shares (9,475 units at $2.95), decreasing direct ownership by 0.54% to 1,731,869 units (SEC Form 4) to satisfy tax liability](https://www.quantisnow.com/insight/chief-executive-officer-magrath-george-sold-27926-worth-of-shares-6649654)
- 2026-07-27 20:06 UTC [SEC Form 4] [Chief Financial Officer Gagnon Robert E. sold $22,942 worth of shares (7,783 units at $2.95), decreasing direct ownership by 1% to 584,375 units (SEC Form 4) to cover taxes](https://www.quantisnow.com/insight/chief-financial-officer-gagnon-robert-e-sold-22942-worth-of-6649650)

## More

- Live page with ratings, short volume, options and peers: https://www.quantisnow.com/company/IRD
- Earnings history: https://www.quantisnow.com/earnings/IRD
- Dividend history: https://www.quantisnow.com/dividends/IRD
- Insider transactions: https://www.quantisnow.com/insiders/IRD
- Options chain: https://www.quantisnow.com/options/IRD
- SEC 8-K filings only: https://www.quantisnow.com/company/IRD/8-k
- RSS and alerts for IRD: https://www.quantisnow.com/docs/rss-feeds.md